Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) EBT Margin (2016 - 2025)

Cardiff Oncology's EBT Margin history spans 15 years, with the latest figure at 2969.14% for Q4 2025.

  • For Q4 2025, EBT Margin rose 483550.0% year-over-year to 2969.14%; the TTM value through Dec 2025 reached 7732.88%, down 109663.0%, while the annual FY2025 figure was 7732.88%, 108691.0% down from the prior year.
  • EBT Margin for Q4 2025 was 2969.14% at Cardiff Oncology, up from 9381.67% in the prior quarter.
  • Across five years, EBT Margin topped out at 2969.14% in Q4 2025 and bottomed at 14964.86% in Q1 2022.
  • The 5-year median for EBT Margin is 7970.92% (2021), against an average of 8921.75%.
  • The largest annual shift saw EBT Margin surged 963902bps in 2024 before it plummeted -744973bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 7162.41% in 2021, then fell by -2bps to 7337.5% in 2022, then increased by 19bps to 5976.92% in 2023, then crashed by -31bps to 7804.64% in 2024, then surged by 62bps to 2969.14% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's EBT Margin are 2969.14% (Q4 2025), 9381.67% (Q3 2025), and 11522.31% (Q2 2025).